Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/8992
Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies
Euro Surveill. 2018 Mar;23(9).
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
Europe | case control study | influenza | influenza vaccination | influenza vaccine effectiveness | multicentre study
Adolescent | Adult | Aged | Child | Child, Preschool | Europe | European Union | Female | Humans | Infant | Infant, Newborn | Influenza A Virus, H1N1 Subtype | Influenza A Virus, H3N2 Subtype | Influenza B virus | Influenza Vaccines | Influenza, Human | Male | Middle Aged | Pandemics | Treatment Outcome | Vaccination | Seasons
Files in this item
- Interim2017_18InfluenzaSeasona ...